Indofarma (INAF) Stock Overview
Manufactures and sells pharmaceutical products in Indonesia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
INAF Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PT Indofarma Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp126.00 |
| 52 Week High | Rp725.00 |
| 52 Week Low | Rp126.00 |
| Beta | -0.049 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -74.29% |
| 3 Year Change | -94.50% |
| 5 Year Change | -90.74% |
| Change since IPO | -38.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| INAF | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -0.6% |
| 1Y | -74.3% | -0.4% | -4.8% |
Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: INAF underperformed the ID Market which returned 14.4% over the past year.
Price Volatility
| INAF volatility | |
|---|---|
| INAF Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in ID Market | 13.5% |
| 10% least volatile stocks in ID Market | 3.6% |
Stable Share Price: INAF has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine INAF's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1918 | 900 | . Yeliandriani | indofarma.id |
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutical, and medical equipment; and engages in herb infusion, health support, private polyclinic, general practitioner, dentist, and internet trading applications activities.
PT Indofarma Tbk Fundamentals Summary
| INAF fundamental statistics | |
|---|---|
| Market cap | Rp390.51b |
| Earnings (TTM) | -Rp702.59b |
| Revenue (TTM) | Rp269.35b |
Is INAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INAF income statement (TTM) | |
|---|---|
| Revenue | Rp269.35b |
| Cost of Revenue | Rp445.42b |
| Gross Profit | -Rp176.06b |
| Other Expenses | Rp526.52b |
| Earnings | -Rp702.59b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -226.69 |
| Gross Margin | -65.37% |
| Net Profit Margin | -260.84% |
| Debt/Equity Ratio | -81.2% |
How did INAF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/28 09:58 |
| End of Day Share Price | 2024/07/01 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PT Indofarma Tbk is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yohan Setio | PT Mandiri Sekuritas |
| Guntur Hariyanto | PT PEFINDO |